Dual antiplatelet therapy of clopidogrel plus aspirin versus aspirin monotherapy in patients with Coronary Artery Disease (CAD): a systematic review and meta-analysis
Main Article Content
Keywords
aspirin, coronary artery disease, dual antiplatelet therapy, meta-analysis
Abstract
Background: Aspirin is the most commonly used for treatment in patients with coronary artery disease (CAD). However, there are many evidences from several trials suggested that dual antiplatelet therapy (DAPT) might exhibit a better outcome and more effective than aspirin monotherapy. Thus, we aimed to assess the effect of DAPT versus aspirin monotherapy in patients with CAD.
Methods: Electronic databases were performed in PubMed, EMBASE, and Cohrane from Januari 2005 until March 2021. We searched for randomized control trials comparing DAPT versus aspirin monotherapy in patients with CAD. Pooled effects estimates were reported as an odds ratio (OR) with 95% confidence intervals (CI) and calculated using random effects model. RevMan 5.4 software was used for data analysis.
Results: Five randomized control trials with a total of 8,203 participants met the inclusion critera. DAPT was found to have an association in reducing the risk of major adverse cardiovascular events (OR 0.72; 95% CI 0.57-0.90; p = 0.003; I2 = 17%) and death events (OR 0.62; 95% CI 0.49-0.79; p < 0.0001; I2 = 0%) compared with aspirin monotherapy. Yet, there were no significant difference in myocardial infarction events (OR 0.78; 95% CI 0.57-1.07; p = 0.13; I2 = 28%) and bleeding events (OR 1.65; 95% CI 0.97-2.81; p = 0.06; I2 = 0%) between two groups.
Conclusions: DAPT treatment has a significant effect in reducing the risk of major cardiovascular and death events without a significant effect in myocardial infarction and bleeding events compared with aspirin monotherapy.
References
2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients : nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36:1163–70.
3. Pearson T a., Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106(3):388–91.
4. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF / AHA / SCAI Guideline for Percutaneous Coronary Intervention. JAC [Internet]. 2011;58(24):e44–122. Available from: http://dx.doi.org/10.1016/j.jacc.2011.08.007
5. Vandvik PO, Lincoff a. M, Gore JM, Gutterman DD, Sonnenberg F a., Alonso-Coello P, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 SUPPL.):e637S – e668S.
6. Graham MM, Sessler DI, Parlow JL, Biccard BM, Guyatt G, Leslie K, et al. Aspirin in Patients With Previous Percutaneous Coronary Intervention Undergoing Noncardiac Surgery. Ann Intern Med. 2018 Feb;168(4):237–44.
7. Committee CS. A randomised , blinded , trial of clopidogrel versus aspirin in patients at risk of ischaemic events ( CAPRIE ). Lancet. 1996;348(9038):1329–39.
8. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION. N Engl J Med. 2001;345(7):494–502.
9. Agarwal N, Mahmoud AN, Patel NK, Jain A, Garg J, Mojadidi MK, et al. Meta-Analysis of Aspirin Versus Dual Antiplatelet Therapy Following Coronary Artery Bypass Grafting. Am J Cardiol [Internet]. 2017;121(1):32–40. Available from: https://doi.org/10.1016/j.amjcard.2017.09.022
10. Deo S V, Dunlay SM, Shah IK, Altarabsheh SE, Erwin PJ, Boilson BA, et al. Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting : Is There Any Benefit ? A Systematic Review and Meta-Analysis. J Card Surg. 2013;28:109–16.
11. Zhou Y, Wei X, Lu J, Ye X, Wu M, Xu J, et al. Effects of Combined Aspirin and Clopidogrel Therapy on Cardiovascular Outcomes : A Systematic Review and Meta-analysis. PLoS One. 2012;7(2).
12. Yuan J, Xu GM, Ding J. Aspirin Versus Clopidogrel Monotherapy for the Treatment of Patients with Stable Coronary Artery Disease : A Systematic Review and Meta-Analysis. Adv Ther [Internet]. 2019;36(8):2062–71. Available from: https://doi.org/10.1007/s12325-019-01004-6
13. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD. The Cochrane Collaboration ’ s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:1–9.
14. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.
15. Sun JCJ, Teoh KHT, Lamy A, Sheth T, Ellins M Lou, Jung H, et al. Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study. Am Heart J. 2010 Dec;160(6):1178–84.
16. Ebrahimi R, Gupta S, Carr BM, Collins J, Grover FL, Quin JA, et al. Comparison of Outcomes and Costs Associated With Aspirin ± Clopidogrel After Coronary Artery Bypass. Am J Cardiol [Internet]. 2018;121(6):709–14. Available from: https://doi.org/10.1016/j.amjcard.2017.12.010
17. Benedetto U, Altman DG, Gerry S, Gray A, Lees B, Flather M, et al. Impact of dual antiplatelet therapy after coronary artery bypass surgery on 1-year outcomes in the Arterial Revascularization Trial. Eur J cardio-thoracic Surg Off J Eur Assoc Cardio-thoracic Surg. 2017 Sep;52(3):456–61.
18. Kulik A, Le May MR, Voisine P, Tardif J-C, Delarochelliere R, Naidoo S, et al. Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. Circulation. 2010 Dec;122(25):2680–7.
19. Al-zakwani I, Alawi A. Impact of Dual versus Single Antiplatelet Therapy on Major Cardiovascular Outcomes in Patients with Acute Coronary Syndrome in the Arabian Gulf. Med Princ Pract. 2020;29:181–7.
20. Khan SU, Talluri S, Rahman H, Lekkala M, Khan MS, Riaz H, et al. Meta-analysis of efficacy and safety of dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass grafting. Eur J Prev Cardiol. 2018;1–4.
21. Bhatt DL, Bertrand ME, Berger PB, Allier PLL, Moussa I, Moses JW, et al. Meta-Analysis of Randomized and Registry Comparisons of Ticlopidine With Clopidogrel After Stenting. J Am Coll Cardiol [Internet]. 2002;39(1):9–14. Available from: http://dx.doi.org/10.1016/S0735-1097(01)01713-2
22. Liang L-R, Ma Q, Feng L, Qiu Q, Zheng W, Xie W-X. Long-term effect of clopidogrel in patients with and without diabetes: A systematic review and meta-analysis of randomized controlled trials. World J Diabetes. 2020;11(4):137–49.
23. Squizzato A, Bellesini M, Takeda A, Middeldorp S, Mp D. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events ( Review ). Cochrane Database Syst Rev. 2017;(12).
24. Ibrahim A, Al-Lawati J, Alsheikh-Ali AA, Almahmeed W, Rashed W, Al-Mulla A, et al. Impact of Dual versus Single Antiplatelet Therapy on Major Cardiovascular Outcomes in Patients with Acute Coronary Syndrome in the Arabian Gulf. Med Princ Pract. 2020;29(2):181-187.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Haidar Ali Hamzah, Department of Medicine, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
Department of Medicine, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
Theodorus, Department of Pharmacology, Universitas Sriwijaya, Palembang, Indonesia
Department of Pharmacology, Universitas Sriwijaya, Palembang, Indonesia